Discover 532 paid clinical trials in Hershey, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 532
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for
Malignant Female Reproductive System Neoplasm,
Location: Mechanicsburg PA, Baltimore MD, Willow Grove PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06126276
Phase 2, Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
for
Coronary Arterial Disease (CAD),
Location: Mechanicsburg PA, York PA, Falls Church VA, Brooklyn NY,
Sponsor: Boston Scientific Corporation
Sex: All
Age: 18+
Code: NCT06959524
Recruiting
Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)
for
Chronic Diabetic Foot Ulcers
Location: York PA, New York NY, Ford City PA, Kittanning PA,
Sponsor: SerenaGroup, Inc.
Sex: All
Age: 18+
Code: NCT04457752
Recruiting
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
for
Metastatic Prostate Cancer
Location: Lancaster PA, Baltimore MD, Silver Spring MD,
Sponsor: ORIC Pharmaceuticals
Sex: Male
Age: 18+
Code: NCT05413421
Phase 1, Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
for
Metastatic Castration Resistant Prostate Cancer
Location: Lancaster PA, Bala-Cynwyd PA, Canton OH, Charlotte NC,
Sponsor: ORIC Pharmaceuticals
Sex: Male
Age: 18+
Code: NCT07723248
Phase 3, Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
for
Metastatic Castration Sensitive Prostate Cancer (mCSPC),
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: Lancaster PA, Towson MD, Bala-Cynwyd PA, North Hills NY,
Sponsor: Dendreon
Sex: Male
Age: 18+
Code: NCT06134232
Phase 2, Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for
Non-small Cell Lung Cancer
Location: Lancaster PA, Annapolis MD, New York NY, Syracuse NY,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06561386
Phase 3, Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
for
Urinary Bladder Neoplasms, Neoplasm Metastasis,
Location: Lancaster PA, Baltimore MD, Philadelphia PA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT05614739
Phase 1, Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
for
Colorectal Cancer
Location: Lancaster PA, Philadelphia PA, Fairfax VA,
Sponsor: Criterium, Inc.
Sex: All
Age: 18+
Code: NCT06992258
Phase 2, Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
for
Non-small Cell Lung Cancer
Location: Lancaster PA, Hackensack NJ, Fredericksburg VA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07190248
Phase 3, Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)